As discussed earlier, AstraZeneca surpassed Wall Street analyst estimates for earnings per share (or EPS) and revenues and reported EPS of $1.03 on revenues of ~$5.8 billion in 4Q17, a 3% increase in revenues as compared to revenues of 4Q16. AstraZeneca’s stock price has increased by nearly 14.9% over the last 12 months but decreased by ~2.6% in 2018 year-to-date. Wall Street analysts have a 12-month target price of $39.09 per share as compared to the last price of $33.78 per share as of March 8, 2018.

Israeli drugmaker Teva (TEVA.TA) rebuffed EU antitrust charges of making an illegal deal with rival Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug at a hearing on Tuesday. The European Commission charged the company with the pay-for-delay drug deal in July last year, after hitting Denmark's Lundbeck (LUN.CO), U.S. giant Johnson & Johnson (JNJ.N) and French drugmaker Servier over similar practices in recent years. "Teva has responded to the statement of objections robustly, and has attended the oral hearing today," the company said in a statement, referring to the EU charge sheet.

Israeli drugmaker Teva (TEVA.TA) rebuffed EU antitrust charges of making an illegal deal with rival Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug at a hearing on Tuesday. The European Commission charged the company with the pay-for-delay drug deal in July last year, after hitting Denmark's Lundbeck (LUN.CO), U.S. giant Johnson & Johnson (JNJ.N) and French drugmaker Servier over similar practices in recent years. "Teva has responded to the statement of objections robustly, and has attended the oral hearing today," the company said in a statement, referring to the EU charge sheet.

After two years on the sidelines, Morgan Stanley is taking a more bullish bet on Mylan NV (NASDAQ: MYL ). A Tuesday upgrade boosted Mylan's ratings ratio to 13 Buys and seven Holds. The Rating Analyst ...

Mylan (MYL) is on the move Tuesday, thanks to an upgrade from Morgan Stanley. Analyst David Risinger boosted his rating on the stock to Overweight from Equal Weight and raised his price target to $50 from $39. Risinger writes that he's bullish on Mylan because it has better growth prospects than its peers, thanks to its pipeline. Other analysts have also argued that Mylan is the only specialty pharma stock worth buying, and the stock got a boost after reporting upbeat earnings earlier this month.